Financial Assistance

CareZ connects you to financial support when you need it.

Alpha-1 financial assistance and resources

Once you are enrolled in Zemaira CareZ, your CareZ Coordinator will work with you to understand your financial situation, educate you on your insurance coverage, and inform you of the various programs that may be available to help you afford your Zemaira therapy.

If you are concerned about affording therapy, we have programs that are designed to help you. A CareZ Coordinator can help you if:

  • You have a high co-pay, co-insurance, or other out-of-pocket costs related to paying for your Zemaira.
  • You are experiencing a gap in your medical insurance coverage or your healthcare plan has turned down paying for your Zemaira prescription.
  • You have no medical insurance or prescription drug coverage, or you are underinsured.

During open enrollment periods, your CareZ Coordinator can also provide insurance counseling to help you identify insurance plan options that take into consideration your Zemaira therapy, as well as any other prescriptions and medical needs that you may have.

Do you have state- or federally funded insurance?

If you have public insurance such as Medicare, Medicaid, or Veterans Health Insurance, financial support for co-pays or premium assistance may be available through a non-profit organization. CSL Behring provides substantial funding to this organization to ensure that patients can get access to the therapy they need.

Do you have private insurance?

  • The Zemaira QuickAccessSM program provides patients who have not been previously treated with Zemaira with up to 4 weeks of free Zemaira and up to $3000 in co-pay assistance annualy, renewable every year.
  • If you are unable to afford your insurance premium or co-pays, funding may be available through a non-profit organization.
  • The CSL Behring AssuranceSM program allows you to earn CSL Behring Assurance points for every month of continuous product use. The points are redeemable for product in the event that you lose your insurance coverage. Enrollment is free, simply contact a CareZ Coordinator.

Uninsured or underinsured? Denied coverage?

You may be faced with difficult insurance situations, including lack of insurance, a lapse in coverage, and denied therapies, that may prevent access to your Zemaira therapy.

  • If your insurance provider denies coverage for Zemaira therapy, your CareZ Coordinator can help you and your physician appeal that decision.
  • If you are uninsured or underinsured, Zemaira CareZ can help identify cost-effective insurance options, including Part D plans, that best meet your personal insurance needs.
  • Depending on your situation, your CareZ Coordinator may be able to refer you to the CSL Behring Patient Assistance ProgramSM. This program provides Zemaira free of charge if you do not have prescription drug insurance or your medical coverage does not provide adequate benefits to cover your Zemaira prescription and you meet specific financial and medical criteria.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

Zemaira may not be suitable for everyone; for example, people with known hypersensitivity to components used to make Zemaira, those with a history of anaphylaxis or severe systemic response to A1-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to Zemaira include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because Zemaira is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

CSL Behring

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® and CareZ® are registered trademarks of CSL Behring LLC.
CSL Behring AssuranceSM and CSL Behring Patient Assistance ProgramSM are service marks of CSL Behring LLC.
Zemaira QuickAccessSM is a service mark of CSL Behring LLC.

© 2017 CSL Behring. The product information presented on this site is intended for US residents only.
ZMR14-04-0006 7/2014